1. DOP51 Mucosa-associated microbial signatures associate with objective response prior to the start of anti-TNFα but not vedolizumab or ustekinumab in Crohn's disease patients. (30th January 2023) Authors: Hageman, I; Joustra, V; Zafeiropoulou, K; Davids, M; Hakvoort, T; Probert, F; Satsangi, J; D'Haens, G; De Jonge, W Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P198 An inflammatory serum metabolomic signature predicts response to vedolizumab treatment in people with Crohn's Disease. (21st January 2022) Authors: Radford-Smith, D; Yates, A; Hageman, I; Joustra, V; Li Yim, A; Davids, M; Henneman, P; Hakvoort, T; D'Haens, G; de Jong, W; Anthony, D; Satsangi, J; Probert, F Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P494 A serum metabolite panel predicts Crohn's disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial. (21st January 2022) Authors: Radford-Smith, D; Satsangi, J; Louis, E; Laharie, D; Ding, N; Siegmund, B; D'Haens, G; Erik, H; Yates, A; Anthony, D; Colombel, J F; Probert, F Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i458 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P707 Microbial signature of the colon is not associated with response to vedolizumab in Crohn's disease. (21st January 2022) Authors: Hageman, I; Joustra, V; Li Yim, A; Davids, M; Henneman, P; Hakvoort, T; Probert, F; Satsangi, J; D'Haens, G; De Jonge, W Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i603 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗